California dentists, physicians and other specified licensees who renew their license beginning in April 2021 will see an increase in the regulatory fee assessed annually to cover the “reasonable costs” associated with operating and maintaining CURES 2.0 ― California’s prescription drug monitoring database.
CDA reminds California-licensed dentists that they are required to begin using tamper-resistant prescription pads when prescribing controlled substances no later than Jan. 1, 2021. Also taking effect are two laws related to controlled-substance prescribing for Medicare beneficiaries and reporting requirements for controlled-substance dispensing.
California law requires that prescribers of controlled substances begin using new prescription forms beginning Jan. 1, 2021, to help reduce prescription fraud. The compliant forms contain unique serial numbers and barcodes that are linked to corresponding records in CURES.
A dentist who writes controlled substance prescriptions can now review CURES (Controlled Substance Utilization Review and Evaluation System) for patients for whom the dentist is listed as a prescriber. This ability to review the list is useful when a dentist has misplaced a prescription pad or has had a prescription pad stolen or when a dentist suspects someone is misusing their DEA number.
A new state law requires that tamper-resistant prescription forms for controlled substances have unique serial numbers. These numbers will be linked to corresponding records in California’s prescription-drug monitoring program known as CURES. The requirement is part of Assembly Bill 1753 signed into law last September. New prescription forms should be ordered from a “serial # compliant printer” as indicated on the DOJ’s website.
Many bills were introduced over the past year to combat the opioid epidemic in California, as CDA previously reported. Here is an overview of CDA-supported legislation in the areas of e-prescribing, informed consent, interstate data sharing and prescription-pad requirements, that Gov. Jerry Brown signed into law in September and how these bills will affect the practice of dentistry.
Beginning Oct. 2, all licensees authorized to prescribe, order, administer, furnish or dispense controlled substances in California must, with some exceptions, check a patient’s prescription history in CURES 2.0 before prescribing a Schedule II-IV substance, as CDA first reported in April. One notable exemption to mandatory CURES consultation that applies to dental care and that CDA helped secure is summarized here.
The Department of Justice on April 2 announced that California’s Controlled Substance Utilization Review and Evaluation System, also known as CURES 2.0, is ready for statewide use and that mandatory CURES consultation becomes effective Oct. 2, 2018. Beginning on this date, prescribers must check a patient’s prescription history in CURES 2.0 before prescribing a Schedule II-IV substance, with some exceptions.